Cambrex expands small scale capacity at Charles City plant

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex, has completed an expansion of cGMP small scale capacity at its Charles City plant in Iowa.

“Small scale manufacturing has been identified as being a crucial area where capacity is at a premium within the industry, and this investment has been undertaken to increase our flexibility and reduce potential project bottle necks to benefit our customers,” commented Joe Nettleton, vice president US Operations, Cambrex. “This continues Cambrex’s ongoing commitment to investing in small molecule manufacturing, ensuring that we can meet the challenges of customer project timelines, especially at the key development stages.”

This investment, which follows the recent expansion of large scale manufacturing capabilities at the same site, includes the installation of two 500 gallon glass lined reactors and the creation of a third small scale work centre.

Additionally, the company recently announced it will be constructing a $24 million highly potent API manufacturing facility at the site, which is due to open in 2019.